

NORTH CENTRAL CANCER TREATMENT GROUP

N07C2 Continuation Phase Eligibility Checklist

8/13/2010

Page 1 of 2

N07C2: The Use of Wisconsin Ginseng (*panax quinquefolius*) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

If the patient and physician want to continue with the active agent, or if on placebo, begin the active agent, call (507/284-4130) or fax (507/284-0885) a completed continuation phase eligibility checklist to the Registration Office between 8 a.m. and 4:30 p.m. central time Monday through Friday.

Has the patient ever been on a prior study entered through this Randomization Center? ____ Yes ____ No

If yes: Prior study number _____; prior patient study ID number _____

Registration date (date on) (<i>mm/dd/yyyy</i>) __ __/__ __/____
Patient study ID number (<i>provided at time of Reg/Random</i>) _____
NCCTG member (participant sponsor) _____
NCCTG treating location _____
NCCTG treating physician _____
Institution patient number (local subject number) _____
IRB approval date (<i>mm/dd/yyyy</i>) __ __/__ __/____

Patient study ID number _____

Eligibility Check - Answer questions below (yes/no). All requirements must be confirmed. All dates are to be *mm/dd/yyyy*.

Registration Check

Yes No

	Yes	No
The double-blind phase of the study must be completed prior to the treatment code being broken; that is, after the treating site has received the completed patient questionnaire booklet.	____	____
Treatment cannot begin prior to registering to the continuation phase and must begin ≤ 28 days after registration.	____	____
Study drug availability checked.	____	____
Patient questionnaire booklet availability checked; copies are not acceptable for this submission.	____	____

All responses in above section must be "Yes"

N07C2 Continuation Phase Eligibility Checklist

8/13/2010
Page 2 of 2

Patient study ID number _____

Assigned Treatment

_____ Panax quinquefolius (Wisconsin ginseng)

Person registering _____ Random. Specialist _____
Signature initials

Physician _____ M - D - Y
Signature